Transcatheter Technologies Completes Durability Testing Of Its Prosthetic Aortic Heart Valve, Intrinsic To World’s First ‘Truly Repositionable’ TAVI Device, TRINITY

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

REGENSBURG, Germany--(BUSINESS WIRE)--Transcatheter Technologies GmbH, an emerging medical device company that is developing a third-generation transcatheter aortic valve implantation (TAVI) system—TRINITY—announced today that an independent laboratory has completed ‘advanced wear testing’ (AWT) of the company’s TRINITY valve prosthesis, far exceeding minimum testing standards. Indeed, AWT of the TRINITY heart valve has already completed 600 million cycles, or an estimated 15 years of durability testing.

Help employers find you! Check out all the jobs and post your resume.

Back to news